Find out more about the efficacy of SKYRIZI
Explore the durability of response with SKYRIZI through clinical trials and long-term data in psoriasis and psoriatic arthritis. Start by selecting a study from the menu below.
LONG-TERM DATA
HEAD-TO-HEAD TRIALS
SKYRIZI IN PsA
Featured content
UK-RISN-240179. Date of preparation May 2024.
References
- Reich K, et al. Lancet 2019; 394: 576-586.
- Gordon KB, et al. Lancet 2018; 392: 650-661.
- Warren RB, et al. Risankizumab vs Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD 2020.
- SKYRIZI: Summary of Product Characteristics.
- Gooderham MJ, et al. J Eur Acad Dermatol Venereol 2018; 32(7): 1111-1119.
- Kofoed K, et al. Acta Derm Venereol 2015; 95(2): 133-139.
- Gaffen SL, et al. Nat Rev Immunol 2014; 14(9): 585-600.
- Girolomoni G, et al. J Eur Acad Dermatol Venereol 2017; 31(1): 1616-1626.
- Lynde CW, et al. J Am Acad Dermatol 2014; 71(1): 141-150.
UK-RISN-240143. Date of preparation: May 2024.